Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the area of PDAC microenvironment with the ultimate goal of understanding the interaction between tumors and the microenvironment. The plan is to design new immunotherapy and combination interventions that would accommodate and build on the distinct characteristics of this interaction. It is expected that the interventions will lead to improved responses in pre-clinical models and clinical evaluation either in NCI-based early phase networks (ETCTN), or by industry or cancer centers.

There is a need to better understand the role of inflammation in the genesis and progression of PDAC, the role of different effectors and suppressors of immune responses, the contribution of tumor stroma with the focus on its heterogeneity, and the function of tumor vasculature. Studying tumor-microenvironment interactions in PDAC should lead to the discoveries of vulnerabilities that could be exploited in the design of immunotherapies such as cancer vaccines, checkpoint inhibition, cellular therapies and their combination with other precision medicine interventions and radiation therapy.

The companion FOA of the PDAC Consortium includes:

  • RFA-CA-17-016, " Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)”."


  • Letter of Intent Due Date(s): February 7, 2017
  • Application Due Date(s): March 7, 2017

RFA-CA-17-015​ Expiration Date March 8, 2017

Agency Website



Amount Description

Direct costs are limited to $350,000 per year.

The total project period request may not exceed 5 years.

Funding Type





Medical - Translational

External Deadline

March 7, 2017